干扰素α治疗冠状病毒肺炎的疗效和安全性的系统评价

Systematic review of efficacy and safety of interferon-αin coronavirus pneumonia

目的系统评价干扰素α在既往冠状病毒肺炎的疗效和安全性,探讨其用于新型冠状病毒肺炎(COVID-19)的临床可行性。方法计算机检索PubMed、Web of Science、Embase、中国知网、维普、万方等数据库有关干扰素α用于严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)治疗有效性的队列研究,并检索报刊、网站等作为辅助。检索时间范围为2003年1月到2020年1月30日,采用RevMan5.3软件进行Meta分析。结果通过文献检索,最终纳入5项队列研究。结果提示,干扰素α组死亡率显著低于对照组(OR=0.36,95%CI:0.16~0.78,P=0.01);不良反应发生率与对照组相比无显著差异(OR=2.42,95%CI:0.47~12.58,P=0.64)。结论干扰素α可降低冠状病毒肺炎的死亡率,安全性良好,可能有辅助抗病毒治疗COVID-19的潜在价值。

AIM To systematically evaluate the efficacy and safety of interferon-α(IFN-α)in previous coronavirus pneumonia,and to explore its clinical feasibility for corona virus disease 2019(COVID-19).METHODS The retrieve cohort studies on the efficacy of IFN-αin the treatment of severe acute respiratory syndrome(SARS)and Middle East respiratory syndrome(MERS)were searched from the databases including PubMed,Web of Science,Embase,CNKI,VIP,Wangfang and other databases,and newspapers and websites as supplements.The retrieval time range was from January 2003 to January 30,2020.Meta analysis was performed using RevMan5.3 software.RESULTS Through literature retrieval,5 cohort studies were finally included.The results indicated that the mortality rate of the IFN-αgroup was significantly lower than that of the control group(OR=0.36,95%CI:0.16 to 0.78,P=0.01).The total incidence of adverse reactions have no significant difference compared with the control group(OR=2.42,95%CI:0.47 to 12.58,P=0.64).CONCLUSION IFN-αcan reduce the death rate of coronavirus pneumonia with good safety,and may have the potential value of adjuvant antiviral treatment of COVID-19.